Table 3:

Pexidartinib pharmacodynamics: Fold change in peripheral blood markers compared to baseline

	6–8 Days from C1			14–16 Days from C1			27–29 Days from C1			Repeated Measures ANCOVA
CBC Parameter (Fold Change from Day 1)	N	P*	Med. Fold Change (95% CI)	N	P*	Med. Fold Change (95% CI)	N	P*	Med. Fold Change (95% CI)	Time Linear	Dose Linear
White blood cell (WBC)	13	0.15	0.89 (0.78, 1.07)	13	0.04	0.85 (0.65, 1.06)	10	0.19	0.81 (0.58, 1.28)	0.007	0.10
Hemoglobin (Hgb)	13	0.08	1.03 (0.97, 1.08)	13	0.02	0.97 (0.91, 1.00)	10	0.37	1.03 (0.95, 1.13)	0.91	0.71
Platelet Count	13	0.24	1.10 (0.84, 1.17)	13	0.64	0.97 (0.83, 1.13)	10	0.43	0.94 (0.79, 1.18)	0.59	0.002
Neutrophils % + bands	13	0.13	1.08 (0.96, 1.13)	13	0.07	1.08 (0.96, 1.13)	10	0.85	0.97 (0.78, 1.30)	0.91	0.26
Immature granulocytes	9	0.01	0.50 (0.08, 0.67)	9	0.01	0.46 (0.30, 0.67)	6	0.44	0.24 (0.00, 2.00)
Lymphocytes %	13	0.79	0.96 (0.81, 1.29)	13	0.95	0.92 (0.87, 1.25)	10	0.28	1.28 (0.47, 1.95)	0.53	0.29
Monocytes %	13	0.002	0.60 (0.40, 0.87)	13	0.002	0.67 (0.52, 0.89)	10	0.05	0.84 (0.26, 1.06)	0.03	0.10
Eosinophils %	10	0.03	0.78 (0.55, 1.04)	11	0.70	0.97 (0.92, 1.53)	8	0.46	0.76 (0.48, 4.19)	0.87	0.79
Basophils %	12	0.16	0.95 (0.50, 1.13)	11	0.04	0.83 (0.50, 1.13)	9	0.01	0.22 (0.00, 0.83)	0.001	0.28
Absolute Neutrophil Count	13	0.74	0.90 (0.77, 1.26)	13	0.41	0.96 (0.64, 1.15)	10	0.49	0.70 (0.46, 1.66)	0.035	0.13
Absolute Immature Granulocyte	9	0.09	0.50 (0.10, 1.00)	9	0.02	0.50 (0.19, 1.00)	6	0.69	0.20 (0.00, 2.50)
Absolute Lymphocyte Count	13	0.49	0.97 (0.68, 1.20)	13	0.05	0.88 (0.73, 1.03)	10	0.36	0.86 (0.60, 1.21)	0.075	0.56
Absolute Monocyte Count	13	0.001	0.58 (0.35, 0.81)	13	0.0002	0.56 (0.40, 0.89)	10	0.002	0.64 (0.26, 0.88)	0.0003	0.95
Absolute Eosinophil Count	10	0.01	0.76 (0.50, 1.07)	11	0.92	1.00 (0.81, 1.27)	8	0.25	0.63 (0.31, 5.37)	0.73	0.97
Absolute Basophil Count	12	0.06	0.92 (0.50, 1.00)	11	0.01	0.67 (0.50, 1.00)	9	0.01	0.33 (0.00, 0.67)	0.0006	0.057

^*Two-tailed unadjusted signed rank test p-value for Mu=1